{
  "id": "56d06e043975bb303a000011",
  "type": "factoid",
  "question": "In which breast cancer patients can palbociclib be used?",
  "ideal_answer": "Palbociclib is useful for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25524798",
    "http://www.ncbi.nlm.nih.gov/pubmed/25792301",
    "http://www.ncbi.nlm.nih.gov/pubmed/26236140"
  ],
  "snippets": [
    {
      "text": "Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26236140",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We aimed to assess the safety and efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25524798",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:1612",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001943"
  ],
  "exact_answer": "hormone receptor-positive, human epidermal growth factor receptor 2-negative"
}